Position in ASND
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$0
-$426 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Derivatives in ASND
reported options exposure · as of Mar 31, 2026CallValue
$11,436,500
CallShares
50,000
PutValue
$2,287,300
PutShares
10,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026PEAK6 LLC holds $24,388,144 across 19 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
108,604 | $5,166,292 | |
| 2 | BNTX |
BioNTech SE
|
43,054 | $3,826,639 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,716 | $3,214,732 | |
| 4 | MRNA |
Moderna, Inc.
|
60,583 | $3,077,616 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
34,419 | $2,584,522 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,955 | $2,283,150 | |
| 7 | INSM |
INSMED Inc
|
7,926 | $1,296,059 | |
| 8 | DNA |
Ginkgo Bioworks Holdings, Inc.
|
107,163 | $656,909 |
All Filings in ASND
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,436,500 | 50,000 | Call | Defined | 2026-05-14 | |
| 2026-03-31 | $2,287,300 | 10,000 | Put | Defined | 2026-05-14 | |
| 2025-12-31 | $426 | 2 | Shares | Defined | 2026-03-12 | |
| 2025-12-31 | $10,662,000 | 50,000 | Call | Defined | 2026-03-12 | |
| 2025-12-31 | $2,132,400 | 10,000 | Put | Defined | 2026-03-12 | |
| No filing history on record for this holder in this stock. | ||||||